Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Cell Medica
Cell Medica
Activities:
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Cell Medica appoints new CEO
Design & Build
Cell and Gene Therapy Catapult opens manufacturing centre
More than £60 million of UK government investment is being used to develop the new centre, which aims to accelerate growth of the industry in the UK
Recruitment
New CFO to lead Cell Medica financing
Research & Development
Cell Medica appoints CSO to accelerate R&D for CAR and TCR programmes
Media
Cell Medica acquires WT1 cancer immunotherapy from CGT Catapult
The acquisition transfers rights for WT1-TCR cell therapy from CGT Catapult to Cell Medica, also establishing development and manufacturing collaboration
Research & Development
Cell Medica and UCL to develop T cell receptor cancer products
Cell Medica gains an exclusive worldwide option and licensing agreement for these technologies
Pharmaceutical
Cell Medica begins commercial production at cell therapy facility in Germany
The first product has been manufactured and delivered to the patient
Subscribe now